The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: Implications for echinocandin therapy in neonates

Journal of Infectious Diseases

Volumn 197, Issue 1, 2008, Pages 163-171

  Hope, William W ^a,d   Mickiene, Diana ^a,c   Petraitis, Vidmantas ^a,c   Petraitiene, Ruta ^a,c   Kelaher, Amy M ^a   Hughes, Joanna E ^a   Cotton, Margaret P ^a   Bacher, John ^b   Keirns, James J ^e   Buell, Donald ^e   Heresi, Gloria ^f   Benjamin Jr , Daniel K ^g   Groll, Andreas H ^a,h   Drusano, George L ^d   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c SAIC FREDERICK INC   (United States)

^d ORDWAY RESEARCH INSTITUTE   (United States)

^e ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^g DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^h UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ECHINOCANDIN; MICAFUNGIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; BRAIN; CANDIDA; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; DRUG PENETRATION; EXPERIMENTAL STUDY; FEMALE; HEMATOGENOUS CANDIDA MENINGOENCEPHALITIS; MENINGOENCEPHALITIS; MICROBIOLOGY; MONTE CARLO METHOD; NEWBORN; NONHUMAN; PEDIATRICS; PHARMACODYNAMICS; PHARMACOKINETICS; POPULATION; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDIASIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHINOCANDINS; FEMALE; HUMANS; INFANT, NEWBORN; LIPOPROTEINS; MENINGOENCEPHALITIS; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; RABBITS;

EID: 39349084676     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/524063     Document Type: Article

References (30)

1. Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006; 117:84-92.
2. Fernandez M, Moylett EH, Noyola DE, Baker CJ. Candidal meningitis in neonates: a 10-year review. Clin Infect Dis 2000; 31:458-63.
3. Friedman S, Richardson SE, Jacobs SE, O'Brien K. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J 2000; 19:499-504.
4. Cohen-Wolkowiez M, Smith PB, Mangum B, et al. Neonatal Candida meningitis: significance of cerebrospinal fluid parameters and blood cultures. J Perinatol 2007; 27:97-100.
5. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362:1142-51.
6. Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004; 23:1093-7.
7. Natarajan G, Lulic-Botica M, Rongkavilit C, Pappas A, Bedard M. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005; 25:770-7.
8. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006; 25:1110-5.
9. Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000; 182:274-82.
10. Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press, 1996.
11. Walsh TJ, Bacher J, Pizzo PA. Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab Anim Sci 1988; 38:467-71.
12. Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasisandinvasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46:1857-69.
13. Leary R, Jelliffe R, Schumitzky A, van Guilder M. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. In: Proceedings of the Fourteenth IEEE Symposium on Computer Based Medical Systems. Bethesda, MD: IEEE Computer Society, 2001:389-94.
14. D'Argenio DZ, Schumitzky A. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Los Angeles: Biomedical Simulations Resource, University of Southern California, 1997. Available at: http://bmsr.usc.edu/. Accessed November 2007.
15. Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005; 49:5058-68.
16. Hope WW, Warn PA, Sharp A, et al. Optimization of the dosage of 5-fluorocytosine in combination with amphotericin B for invasive candidiasis: a pharmacodynamic rationale for reducing dosing. Antimicrob Agents Chemother 2007; 51:3760-2.
17. Gumbo T, Hiemenz J, Mal L, Keirns JJ, Buell DN, Drusano GL. Population pharmacokinetics of micafungin in adult patients. Diagn Microbiol Infect Dis (in press).
18. Jafari HS, Saez-Llorens X, Grimprel E, Argyle JC, Olsen KD, McCracken GH Jr. Characteristics of experimental Candida albicans infection of the central nervous system in rabbits. J Infect Dis 1991; 164:389-95.
19. Jafari HS, Saez-Llorens X, Severien C, et al. Effects of antifungal therapy on inflammation, sterilization, and histology in experimental Candida albicans meningitis. Antimicrob Agents Chemother 1994; 38:83-9.
20. Kearney BP, Aweeka FT. The penetration of anti-infectives into the central nervous system. Neurol Clin 1999; 17:883-900.
21. Su Y, Sinko PJ. Drug delivery across the blood-brain barrier: Why is it difficult? How to measure and improve it? Expert Opin Drug Deliv 2006; 3:419-35.
22. Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006; 42:1171-8.
23. Lutsar I, McCracken GH Jr, Friedland IR. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 1998; 27:1117-27.
24. Schaad UB, Nelson JD, McCracken GH Jr. Pharmacology and efficacy of vancomycin for staphylococcal infections in children. Rev Infect Dis 1981; 3:S282-8.
25. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44:343-500.
26. Lopez-Berestein G, Rosenblum MG, Mehta R. Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Deliv 1984; 1:199-205.
27. Perfect JR, Durack DT. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother 1985; 16:81-6.
28. Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 2005; 41:e27-8.
29. Pelletier R, Alarie I, Lagace R, Walsh TJ. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med Mycol 2005; 43:559-64.
30. Santos RP, Sanchez PJ, Mejias A, et al. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. Pediatr Infect Dis J 2007; 26:364-6.